公开(公告)号：US20210060160A1

公开(公告)日：2021-03-04

申请号：US17020108

申请日：2020-09-14

申请人： UCB PHARMA, S.A.

发明人： Martyn K. Robinson

IPC分类号： A61K39/395 ,  A61K33/42 ,  A61K45/06 ,  C07K16/22

摘要： The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.

公开(公告)号：US10799583B2

公开(公告)日：2020-10-13

申请号：US15887299

申请日：2018-02-02

申请人： UCB PHARMA, S.A.

发明人： Martyn K. Robinson

IPC分类号： A61K39/395 ,  C07K16/18 ,  C07K16/22 ,  A61K45/06 ,  A61K33/42 ,  A61K39/00

摘要： The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.

公开(公告)号：US20200048372A1

公开(公告)日：2020-02-13

申请号：US16508967

申请日：2019-07-11

申请人： UCB PHARMA S.A.

发明人： Ralph Adams ,  Laura Hancock ,  Sam Philip Heywood

IPC分类号： C07K16/46 ,  C07K16/28 ,  C07K16/24 ,  C07K16/18

摘要： A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab′ fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest, wherein the two single domain antibodies are linked by a disulfide bond. There is also provided particular dual specificity antibody fusion proteins comprising a Fab or Fab′ fragment and one or more single domain antibodies which may be stabilised by a disulfide bond therebetween.

公开(公告)号：US20190127489A1

公开(公告)日：2019-05-02

申请号：US16124650

申请日：2019-01-21

申请人： UCB PHARMA S.A.

发明人： David Paul Humphreys ,  Emma Dave ,  Laura Griffin ,  Sam Philip Heywood

IPC分类号： C07K16/46 ,  C07K16/18 ,  C07K16/24 ,  C07K16/00

摘要： The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.

公开(公告)号：US10189897B2

公开(公告)日：2019-01-29

申请号：US14977688

申请日：2015-12-22

申请人： UCB PHARMA, S.A.

发明人： Mariangela Spitali ,  Jonathan Symmons ,  Richard Whitcombe ,  Mark Robert Pearce-Higgins

IPC分类号： C07K1/18 ,  C07K1/36 ,  C07K16/24

摘要： The present invention relates to a process for the purification of an antibody fragment from a periplasmic cell extract comprising a first cation exchange chromatography step and a second anion exchange chromatography step.

公开(公告)号：US10017575B2

公开(公告)日：2018-07-10

申请号：US15242135

申请日：2016-08-19

申请人： UCB Pharma S.A.

发明人： Alastair David Griffiths Lawson ,  Andrew Malcolm Nesbitt ,  Andrew George Popplewell ,  Stevan Graham Shaw ,  Diana Shpektor ,  Yi Zhang

IPC分类号： C07K16/18 ,  C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  C07K14/705 ,  A61K39/00

CPC分类号： C07K16/2878 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K14/70578 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

摘要： The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

公开(公告)号：US20180169235A1

公开(公告)日：2018-06-21

申请号：US15887299

申请日：2018-02-02

申请人： UCB PHARMA, S.A.

发明人： Martyn K. Robinson

IPC分类号： A61K39/395 ,  A61K45/06 ,  C07K16/22 ,  A61K33/42 ,  A61K39/00 ,  C07K16/18

摘要： The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.

公开(公告)号：US20180111986A1

公开(公告)日：2018-04-26

申请号：US15534635

申请日：2015-12-11

申请人： AMGEN INC. ,  UCB PHARMA S.A.

发明人： Martyn Kim Robinson ,  Michael Stuart Ominsky ,  Xiaodong Li ,  Hua Zhu Ke

IPC分类号： C07K16/22 ,  A61P19/08 ,  A61K39/395 ,  A61K45/06 ,  A61P19/10

CPC分类号： C07K16/22 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  A61P19/08 ,  A61P19/10 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/94

摘要： The invention relates to the treatment of bone disorders. In particular, the invention provides an approach involving administration of a high initial dose or doses of an sclerostin antibody to bring about a rapid increase in bone formation, followed by administration of lowers doses of the antibody to give a sustained lower rate of bone formation after the initial burst of bone formation. The invention also provides an approach involving decreasing dosing frequency with such an antibody to control bone formation. The approaches may be used in particular in those subjects who would benefit most from such an initial rapid burst of bone formation. Examples of such subjects include subjects who have been recently diagnosed or are experiencing severe symptoms of the disorder, as well as those subjects who have been administered a different treatment for the bone disorder which is proving ineffective. The approaches may be used in combination with each other.

公开(公告)号：US09791462B2

公开(公告)日：2017-10-17

申请号：US14626274

申请日：2015-02-19

申请人： UCB PHARMA S.A.

发明人： Mary E. Brunkow ,  David J. Galas ,  Brian Kovacevich ,  John T. Mulligan ,  Bryan W. Paeper ,  Jeffrey Van Ness ,  David G. Winkler

IPC分类号： G01N33/68 ,  G01N33/84 ,  C07K14/475 ,  A61K38/18 ,  A61K45/06 ,  G01N33/74 ,  C07K14/51 ,  C07K16/18 ,  C07K16/22 ,  C12Q1/68 ,  A61K39/395 ,  A61K48/00

CPC分类号： G01N33/74 ,  A01K2217/05 ,  A01K2217/075 ,  A61K38/18 ,  A61K39/3955 ,  A61K45/06 ,  A61K48/00 ,  C07K14/475 ,  C07K14/51 ,  C07K16/18 ,  C07K16/22 ,  C07K2317/11 ,  C07K2317/23 ,  C07K2319/00 ,  C12N2799/021 ,  C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/172 ,  G01N33/6872 ,  G01N33/84 ,  G01N2333/47 ,  G01N2333/495 ,  G01N2333/51 ,  G01N2500/02 ,  G01N2500/20

摘要： A novel class or family of TGF-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules.

公开(公告)号：US09657095B2

公开(公告)日：2017-05-23

申请号：US14662538

申请日：2015-03-19

申请人： UCB PHARMA S.A.

发明人： David G. Winkler ,  Jiye Shi ,  John Latham

IPC分类号： A61K39/00 ,  A61K39/395 ,  C07K16/00 ,  C07K16/18 ,  C07K16/22 ,  C12N1/21 ,  C12N5/10 ,  C12N5/12 ,  C12N15/11 ,  C12N15/13 ,  C12N15/63 ,  C07K14/51 ,  A61K47/48 ,  C07K14/475 ,  G01N33/68

CPC分类号： C07K16/22 ,  A61K47/643 ,  A61K47/646 ,  C07K14/475 ,  C07K14/51 ,  C07K16/18 ,  C07K2317/76 ,  G01N33/6854 ,  G01N2333/4704

摘要： Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.